Cargando…

Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline

Background: This study aims to provide guidance for the use of neoadjuvant and adjuvant systemic therapy in women with newly diagnosed stage II–IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma. Methods: EMBASE, MEDLINE, and Cochrane Library were investigated for relevant systemat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirte, Hal, Poon, Raymond, Yao, Xiaomei, May, Taymaa, Ethier, Josee-Lyne, Petz, Lauri, Speakman, Jane, Elit, Laurie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774918/
https://www.ncbi.nlm.nih.gov/pubmed/35049696
http://dx.doi.org/10.3390/curroncol29010022
_version_ 1784636458489872384
author Hirte, Hal
Poon, Raymond
Yao, Xiaomei
May, Taymaa
Ethier, Josee-Lyne
Petz, Lauri
Speakman, Jane
Elit, Laurie
author_facet Hirte, Hal
Poon, Raymond
Yao, Xiaomei
May, Taymaa
Ethier, Josee-Lyne
Petz, Lauri
Speakman, Jane
Elit, Laurie
author_sort Hirte, Hal
collection PubMed
description Background: This study aims to provide guidance for the use of neoadjuvant and adjuvant systemic therapy in women with newly diagnosed stage II–IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma. Methods: EMBASE, MEDLINE, and Cochrane Library were investigated for relevant systematic reviews and phase III trials. Articles focusing on consolidation and maintenance therapies were excluded. Results: For women with potentially resectable disease, primary cytoreductive surgery, followed by six to eight cycles of intravenous three-weekly paclitaxel and carboplatin is recommended. For those with a high-risk profile for primary cytoreductive surgery, neoadjuvant chemotherapy can be an option. Adjuvant chemotherapy with six cycles of dose-dense weekly paclitaxel plus three-weekly carboplatin can be considered for women of Japanese descent. In women with stage III or IV disease, the incorporation of bevacizumab concurrent with paclitaxel and carboplatin is not recommended for use as adjuvant therapy unless bevacizumab is continued as maintenance therapy. Intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel can be considered for stage III optimally debulked women who did not receive neoadjuvant chemotherapy. However, intraperitoneal administration of chemotherapy with bevacizumab should not be considered as an option for stage II–IV optimally debulked women. Discussion: The recommendations represent a current standard of care that is feasible to implement and valued by both clinicians and patients.
format Online
Article
Text
id pubmed-8774918
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87749182022-01-21 Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline Hirte, Hal Poon, Raymond Yao, Xiaomei May, Taymaa Ethier, Josee-Lyne Petz, Lauri Speakman, Jane Elit, Laurie Curr Oncol Guidelines Background: This study aims to provide guidance for the use of neoadjuvant and adjuvant systemic therapy in women with newly diagnosed stage II–IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma. Methods: EMBASE, MEDLINE, and Cochrane Library were investigated for relevant systematic reviews and phase III trials. Articles focusing on consolidation and maintenance therapies were excluded. Results: For women with potentially resectable disease, primary cytoreductive surgery, followed by six to eight cycles of intravenous three-weekly paclitaxel and carboplatin is recommended. For those with a high-risk profile for primary cytoreductive surgery, neoadjuvant chemotherapy can be an option. Adjuvant chemotherapy with six cycles of dose-dense weekly paclitaxel plus three-weekly carboplatin can be considered for women of Japanese descent. In women with stage III or IV disease, the incorporation of bevacizumab concurrent with paclitaxel and carboplatin is not recommended for use as adjuvant therapy unless bevacizumab is continued as maintenance therapy. Intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel can be considered for stage III optimally debulked women who did not receive neoadjuvant chemotherapy. However, intraperitoneal administration of chemotherapy with bevacizumab should not be considered as an option for stage II–IV optimally debulked women. Discussion: The recommendations represent a current standard of care that is feasible to implement and valued by both clinicians and patients. MDPI 2022-01-08 /pmc/articles/PMC8774918/ /pubmed/35049696 http://dx.doi.org/10.3390/curroncol29010022 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Guidelines
Hirte, Hal
Poon, Raymond
Yao, Xiaomei
May, Taymaa
Ethier, Josee-Lyne
Petz, Lauri
Speakman, Jane
Elit, Laurie
Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline
title Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline
title_full Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline
title_fullStr Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline
title_full_unstemmed Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline
title_short Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline
title_sort neoadjuvant and adjuvant systemic therapy for newly diagnosed stage ii–iv epithelial ovary, fallopian tube, or primary peritoneal carcinoma: a practice guideline
topic Guidelines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774918/
https://www.ncbi.nlm.nih.gov/pubmed/35049696
http://dx.doi.org/10.3390/curroncol29010022
work_keys_str_mv AT hirtehal neoadjuvantandadjuvantsystemictherapyfornewlydiagnosedstageiiivepithelialovaryfallopiantubeorprimaryperitonealcarcinomaapracticeguideline
AT poonraymond neoadjuvantandadjuvantsystemictherapyfornewlydiagnosedstageiiivepithelialovaryfallopiantubeorprimaryperitonealcarcinomaapracticeguideline
AT yaoxiaomei neoadjuvantandadjuvantsystemictherapyfornewlydiagnosedstageiiivepithelialovaryfallopiantubeorprimaryperitonealcarcinomaapracticeguideline
AT maytaymaa neoadjuvantandadjuvantsystemictherapyfornewlydiagnosedstageiiivepithelialovaryfallopiantubeorprimaryperitonealcarcinomaapracticeguideline
AT ethierjoseelyne neoadjuvantandadjuvantsystemictherapyfornewlydiagnosedstageiiivepithelialovaryfallopiantubeorprimaryperitonealcarcinomaapracticeguideline
AT petzlauri neoadjuvantandadjuvantsystemictherapyfornewlydiagnosedstageiiivepithelialovaryfallopiantubeorprimaryperitonealcarcinomaapracticeguideline
AT speakmanjane neoadjuvantandadjuvantsystemictherapyfornewlydiagnosedstageiiivepithelialovaryfallopiantubeorprimaryperitonealcarcinomaapracticeguideline
AT elitlaurie neoadjuvantandadjuvantsystemictherapyfornewlydiagnosedstageiiivepithelialovaryfallopiantubeorprimaryperitonealcarcinomaapracticeguideline